ストックスクリーナーアプリを入手
108.26
0.09%
0.10
プレマーケット:
108.33
0.07
+0.06%
前日終値:
$108.16
開ける：
$108.05
24時間の取引高:
1.74M
Relative Volume:
0.85
時価総額：
$21.14B
収益：
$4.58B
当期純損益:
$870.87M
株価収益率:
24.61
EPS:
4.3988
ネットキャッシュフロー:
$945.58M
1週間 パフォーマンス:
+2.42%
1か月 パフォーマンス:
+29.19%
6か月 パフォーマンス:
+77.91%
1年 パフォーマンス:
+34.35%
1日の値動き範囲:
$106.81
$109.28
1週間の範囲:
$103.02
$109.28
52週間の値動き範囲:
$53.56
$109.28
Incyte Corp Stock (INCY) Company Profile
INCY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
108.26 | 20.81B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.19 | 106.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.72 | 68.81B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.74 | 58.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
889.89 | 53.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
377.47 | 36.43B | 4.56B | -176.77M | 225.30M | -1.7177 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-10-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 開始されました | Barclays | Overweight |
| 2025-06-16 | アップグレード | Stifel | Hold → Buy |
| 2025-03-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-18 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 開始されました | UBS | Neutral |
| 2024-10-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-01 | 開始されました | Wolfe Research | Outperform |
| 2024-09-18 | ダウングレード | Truist | Buy → Hold |
| 2024-07-02 | ダウングレード | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 開始されました | Deutsche Bank | Hold |
| 2024-04-23 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 開始されました | Jefferies | Buy |
| 2024-02-14 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-11-21 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-25 | 開始されました | Citigroup | Buy |
| 2023-05-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-04-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 開始されました | Piper Sandler | Overweight |
| 2022-08-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-07-28 | 開始されました | Wells Fargo | Equal Weight |
| 2022-02-09 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-07-20 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-02-10 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 開始されました | Truist | Buy |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-06-16 | 開始されました | The Benchmark Company | Hold |
| 2020-05-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 再開されました | William Blair | Outperform |
| 2020-03-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 再開されました | BofA/Merrill | Neutral |
| 2020-01-03 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2020-01-03 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-10-03 | 開始されました | Mizuho | Buy |
| 2019-09-12 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-09-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 開始されました | Credit Suisse | Neutral |
| 2019-05-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 開始されました | Stifel | Hold |
| 2019-04-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | アップグレード | William Blair | Mkt Perform → Outperform |
すべてを表示
Incyte Corp (INCY) 最新ニュース
Will Incyte Corporation stock see PE expansionJuly 2025 Update & Verified Momentum Watchlists - newser.com
Incyte stock hits 52-week high at 108.81 USD By Investing.com - Investing.com Canada
Incyte stock hits 52-week high at 108.81 USD - Investing.com
Peering Into Incyte Corp's Recent Short Interest - Benzinga
Prelude Therapeutics Reshapes Pipeline With Incyte Deal and Strategic Refocus - MyChesCo
Prelude Strikes $910 Million Deal With Incyte for Groundbreaking JAK2 Cancer Therapy - MyChesCo
Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack - Yahoo Finance
Incyte at Guggenheim Conference: Strategic Focus on Innovation - Investing.com
Can Incyte Corporation stock hit record highs again2025 Performance Recap & Real-Time Volume Analysis - newser.com
Published on: 2025-11-10 05:29:16 - newser.com
Key metrics from Incyte Corporation’s quarterly dataStop Loss & Long-Term Safe Investment Ideas - newser.com
Forecasting Incyte Corporation price range with options data2025 Analyst Calls & AI Enhanced Trade Execution Alerts - newser.com
Can Incyte Corporation stock deliver sustainable ROEMarket Growth Report & Reliable Price Action Trade Plans - newser.com
Incyte Posts 20% Revenue Growth, Raises 2025 Outlook on Strong Drug Demand - MyChesCo
Incyte and Enable Injections Join Forces to Advance At-Home Cancer Treatments - MyChesCo
Incyte to Highlight Innovation at Major Global Healthcare Conferences in November - MyChesCo
Prelude Therapeutics (PRLD): Valuation Snapshot Following Incyte Deal and Pipeline Realignment - Yahoo Finance
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Incyte Corporation stock outperform Dow Jones indexBull Run & Weekly High Momentum Picks - newser.com
How Incyte Corporation stock responds to policy changesWeekly Trend Report & Smart Money Movement Alerts - newser.com
Incyte EVP Denton sells $60,613 in stock By Investing.com - Investing.com South Africa
Incyte EVP Denton sells $60,613 in stock - Investing.com
Will Incyte Corporation (ICY) stock return to pre crash levels2025 Earnings Surprises & Real-Time Volume Trigger Notifications - newser.com
Is It Time to Reevaluate Incyte After Strong Pipeline Update and 52% Price Surge? - Yahoo Finance
Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema - The Joplin Globe
Leading vs lagging indicators on Incyte Corporation performanceJuly 2025 Summary & Real-Time Volume Triggers - newser.com
Incyte (INCY): Buy, Sell, or Hold Post Q3 Earnings? - Barchart.com
Can Incyte Corporation (ICY) stock attract analyst upgradesShort Setup & Smart Money Movement Alerts - newser.com
Incyte (NASDAQ:INCY) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Incyte stock hits 52-week high at 103.93 USD - Investing.com
Prelude Therapeutics (PRLD) Is Up 14.3% After Incyte Option Deal and Pipeline Shift Has the Bull Case Changed? - Yahoo Finance
Incyte Unveils Game-Changing mCALR Trials – What It Means for Blood Cancer Treatment! - Smartkarma
Incyte (INCY) Secures $935M Deal with Prelude Therapeutics for J - GuruFocus
Incyte secures option to acquire Prelude’s JAK2V617F inhibitor program By Investing.com - Investing.com South Africa
Incyte (INCY) Receives Raised Price Target from Piper Sandler | - GuruFocus
Incyte (NASDAQ:INCY) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Incyte aboard, SMARCA2 shift by Prelude enshrouds Foghorn - BioWorld MedTech
Prelude Therapeutics Signs Option Agreement with Incyte - TipRanks
Incyte (NASDAQ:INCY) Upgraded by Guggenheim to Buy Rating - MarketBeat
Incyte (INCY) Secures Option for JAK2V617F Program in $910M Deal - GuruFocus
Incyte secures option to acquire Prelude’s JAK2V617F inhibitor program - Investing.com
Incyte (INCY) Secures Exclusive Option on JAK2V617F Program - GuruFocus
Prelude Therapeutics stock climbs after exclusive JAK2 option deal with Incyte - Investing.com
Prelude Therapeutics Announces Strategic Updates: Prioritizes JAK2V617F and KAT6A Programs, Pauses SMARCA2 Development and Secures $60 Million from Incyte Option Agreement - Quiver Quantitative
Hussman Strategic Advisors Inc. Boosts Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte (INCY) Extends Climb, Hits New High on Bullish Coverage - Insider Monkey
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors - Yahoo Finance
The 5 Most Interesting Analyst Questions From Incyte’s Q3 Earnings Call - Barchart.com
Incyte Corporation (INCY) Stock Forecasts - Yahoo! Finance Canada
Incyte Corporation (INCY) Stock forecasts - Yahoo! Finance UK
Is Incyte Corporation (ICY) stock dividend growth reliableJuly 2025 Sector Moves & Community Consensus Trade Alerts - newser.com
Incyte Corp (INCY) 財務データ
収益
当期純利益
現金流量
EPS
0.53%
大文字化:
|
ボリューム (24 時間):